Announced
Financials
Tags
Friendly
Private Equity
Biotechnology
Single Bidder
Pending
Acquisition
biosimilars
Public
Cross Border
Majority
United Kingdom
Synopsis
Biotage, a life science company, agreed to acquire Astrea Bioseparations, a biotechnology research company, from KKR-backed Gamma Biosciences, a biotechnology company, for $235m. "This move brings together two highly regarded and complementary businesses creating a differentiated player in the field of chromatography. Astrea is quickly becoming one of the leaders in its field with an incredible pipeline of innovation targeting advanced therapeutics. We are excited to join forces with the team at Biotage and leverage the strong foundation that they've established to rapidly grow these businesses together," Matt Gunnison, Gamma Biosciences CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.